Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19369594 | 0.97 | CA2 (0.36) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19358760 | 0.86 | GLP1R (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19369940 | 0.85 | MEN1 (0.37) | CA2CA12CA1CA4CA9 | |
| SCHEMBL3768115 | 0.84 | CA2 (0.39) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19727004 | 0.84 | L3MBTL1 (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19358795 | 0.84 | GLP1R (0.42) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19358777 | 0.84 | GLP1R (0.42) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19821398 | 0.83 | CA2 (0.37) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19726993 | 0.83 | CA2 (0.37) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19726992 | 0.83 | L3MBTL1 (0.41) | CA2CA12CA1CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851658-B2 | Palladium-catalyzed carbon-carbon bond forming reactions | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-14 | — | — | US | disclosed |
| WO-2007008226-A9 | PALLADIUM-CATALYZED CARBON-CARBON BOND FORMING REACTIONS | HARVARD COLLEGE (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070066851-A1 | Palladium-catalyzed carbon-carbon bond forming reactions | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2007-03-22 | — | — | US | disclosed |
| WO-2007008226-A2 | PALLADIUM-CATALYZED CARBON-CARBON BOND FORMING REACTIONS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066851-A1 | Palladium-catalyzed carbon-carbon bond forming reactions | APEX1, PCNA, DNMT3A | CA2 1417/4885CA12 1712/4885CA1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.